Cannabinoids Clinical Trials Collective Safety 
Cannabis Law Report
DECEMBER 14, 2021
(“IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. The trial was conducted as a multiple ascending dose (MAD) study. In addition, 66.7%
Puff Puff Post
MARCH 10, 2020
” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
DECEMBER 2, 2021
(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.
Puff Puff Post
MARCH 10, 2020
” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.
Cannabis Law Report
DECEMBER 7, 2021
Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events.
Veriheal
JUNE 30, 2023
For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.
The Cannigma
JULY 1, 2022
Because of this variability in the plant, and because of a lack of standard methods–like chemical analyses of cannabinoids or terpenes–has led to inconsistent scientific results. This is because these types of studies control the most variables to ensure that the results that come out of the trial are as reliable as possible.
Expert insights. Personalized for you.
52 
Let's personalize your content